Table 3.
Blood morphology, biochemistry, and organ weight in mice bearing KLN205 tumors
| Control | Cyclophosphamide | Compound 1 | Compound 1 | |
|---|---|---|---|---|
| 100 (mg/kg) | 10 (mg/kg) | 20 (mg/kg) | ||
| WBC (103/µl) | 33.2 ± 6.0 | 3.5 ± 0.8* | 37.5 ± 17.4 | 27.8 ± 17.5 |
| LIMF (103/µl) | 15.0 ± 6.0 | 2.4 ± 0.7* | 24.5 ± 16.2 | 17.4 ± 15.2 |
| MON (103/µl) | 3.5 ± 0.8 | 0.3 ± 0.1* | 3.0 ± 0.5 | 2.4 ± 0.6* |
| GRAN (103/µl) | 14.7 ± 2.8 | 0.8 ± 0.2* | 10.0 ± 2.1* | 8.0 ± 2.5* |
| LIMF (%) | 44.4 ± 11.8 | 68.3 ± 5.4* | 59.7 ± 15.0 | 54.2 ± 19.4 |
| MON (%) | 10.7 ± 2.5 | 8.0 ± 1.2* | 9.6 ± 4.3 | 10.9 ± 5.3 |
| GRAN (%) | 45.0 ± 9.5 | 23.7 ± 4.2* | 30.7 ± 10.8* | 34.9 ± 14.1 |
| Erythrocytes (106/µl) | 7.3 ± 1.1 | 5.9 ± 0.7* | 4.7 ± 1.3* | 5.8 ± 1.5 |
| hemoglobin (g/dl) | 11.4 ± 1.2 | 9.4 ± 0.9* | 8.4 ± 2.1* | 10.1 ± 1.8 |
| hematocrit (%) | 31.4 ± 3.0 | 25.0 ± 2.6* | 24.1 ± 5.1* | 27.7 ± 4.0 |
| MCV (fL) | 43.5 ± 4.6 | 42.7 ± 2.6 | 51.9 ± 5.4 | 49.7 ± 7.3 |
| MCH (pg) | 15.8 ± 1.4 | 16.1 ± 0.8 | 17.9 ± 1.1 | 17.9 ± 1.9 |
| MCHC (g/dl) | 36.4 ± 1.0 | 37.7 ± 0.6 | 34.5 ± 1.8 | 36.3 ± 1.3 |
| RDW (%) | 22.0 ± 2.6 | 22.2 ± 2.0 | 24.3 ± 2.5 | 26.5 ± 3.1 |
| platelets (103/µl) | 817.3 ± 67.7 | 1477.0 ± 97.7* | 750.3 ± 125.7 | 942.8 ± 38.3 |
| ALT (U/l) | 29.6 ± 3.9 | 23.0 ± 1.2* | 25.6 ± 2.5* | 24.8 ± 1.6* |
| AST (U/l) | 98.1 ± 11.2 | 66.6 ± 8.6* | 86.8 ± 9.7* | 95.1 ± 12.1 |
| LDH (U/l) | 429.7 ± 67.6 | 325.5 ± 62.0* | 406.4 ± 61.9 | 457.1 ± 85.6 |
| CRE (umol/l) | 6.3 ± 1.2 | 3.1 ± 0.8* | 5.6 ± 1.9 | 4.4 ± 1.1* |
| urea (mmol/l) | 6.2 ± 1.6 | 6.1 ± 1.1 | 7.0 ± 1.8 | 6.2 ± 1.1 |
| Liver (g) | 1.473 ± 0.09 | 1.666 ± 0.11* | 1.384 ± 0.11 | 1.275 ± 0.16* |
| Kidneys (g) | 0.344 ± 0.04 | 0.366 ± 0.02 | 0.327 ± 0.04 | 0.328 ± 0.04 |
Control and groups treated by cyclophosphamide at the dose of 100 mg/kg (1 t/w) or compound 1 at the doses of 10 and 20 mg/kg (5 t/w)
* Statistical significance vs. the control group, (p < 0.05; Mann–Whitney U test, Statistica 10.1)